PIK3CA-Related Overgrowth Spectrum clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
open to eligible people ages up to 100 years
This is a prospective Phase II multi-center study with an initial 16-week, randomized, double-blind, placebo-controlled period, followed by two extension periods to assess the efficacy, safety and pharmacokinetics (PK) of alpelisib in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)
at UCLA UCSF
Our lead scientists for PIK3CA-Related Overgrowth Spectrum research studies include Vivian Chang.
Last updated: